http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Clench, T (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Bioactive Chemicals from Carrot (Daucus carota) Juice Extracts for the Treatment of Leukemia
Rana Zaini,Malcolm R. Clench,Christine L. Le Maitre 한국식품영양과학회 2011 Journal of medicinal food Vol.14 No.11
Overwhelming evidence indicates that consumption of fruits and vegetables with antioxidant properties correlates with reduced risk for cancers, including leukemia. Carrots contain beneficial agents, such as β-carotene and polyacetylenes, which could be effective in the treatment of leukemia. This study investigated the effect of carrot juice extracts on myeloid and lymphoid leukemia cell lines together with normal hematopoietic stem cells. Leukemia cell lines and nontumor control cells were treated with carrot juice extracts for up to 72 hours in vitro. Induction of apoptosis was investigated by using annexin V/propidium iodide staining followed by flow cytometric analysis, and results were confirmed by using 4′-6-diamidino-2-phenylindole morphology. Effects on cellular proliferation were investigated via cell cycle analysis and cell counts. Treatment of leukemia cell lines with carrot juice extract induced apoptosis and inhibited progression through the cell cycle. Lymphoid cell lines were affected to a greater extent than were myeloid cell lines, and normal hematopoietic stem cells were less sensitive than most cell lines. This study has shown that extracts from carrots can induce apoptosis and cause cell cycle arrest in leukemia cell lines. The findings suggest that carrots may be an excellent source of bioactive chemicals for the treatment of leukemia.
-
White, H,Deprez, L,Corbisier, P,Hall, V,Lin, F,Mazoua, S,Trapmann, S,Aggerholm, A,Andrikovics, H,Akiki, S,Barbany, G,Boeckx, N,Bench, A,Catherwood, M,Cayuela, J-M,Chudleigh, S,Clench, T,Colomer, D,Dar Nature Publishing Group 2015 Leukemia Vol.29 No.2
<P>Serial quantification of <I>BCR–ABL1</I> mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of <I>BCR–ABL1</I> (e14a2 mRNA fusion)<I>, BCR</I> and <I>GUSB</I> transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10<SUP>6</SUP>, 1.08±0.11 × 10<SUP>5</SUP>, 1.03±0.10 × 10<SUP>4</SUP>, 1.02±0.09 × 10<SUP>3</SUP>, 1.04±0.10 × 10<SUP>2</SUP> and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 <I>BCR–ABL1</I> testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 <I>BCR–ABL1</I> and three control genes (<I>ABL1, BCR</I> and <I>GUSB</I>). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
